



Docket No.: H1890.0200/P200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gary D. Hodgen, et al.

Application No.: 09/313,625

Group Art Unit: 1617

Filed: May 18, 1999

Examiner: E. Webman

For: CONTROL OF SELECTIVE ESTROGEN  
RECEPTOR MODULATORS

FEB 23 2004

AMENDMENT

INTRODUCTORY COMMENTS

In response to the Office Action mailed September 15, 2003, please reconsider the above-identified U.S. patent application amended as follows:

FEE CALCULATION

Any additional fee required has been calculated as follows:

NO. CLAIMS AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		EXTRA PRESENT	RATE	ADDIT. FEE
TOTAL	13	MINUS	20	* = 0	(\$9 SE or \$18)	\$ 0
INDEP.	1	MINUS	3	** = 0	X (\$42 SE or \$84)	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					X (\$140 SE or \$280)	\$
						0.00
* not less than 20 ** not less than 3					TOTAL	\$

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

**CONTINGENT EXTENSION REQUEST**

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 50-2215.

**SUMMARY OF AMENDMENTS**

**SPECIFICATION**

  X   There are no amendments to the specification.  
       Marked up replacement(s) paragraphs are presented in a separate  
       section.

**CLAIMS**

       There are no amendments to the claims.  
  X   A complete listing of all claims ever present in this case in  
ascending order with status identifier is presented in a separate section.